Research programme: cannabinoid-based therapeutics - Tetra Bio-Pharma/Panag Pharma

Drug Profile

Research programme: cannabinoid-based therapeutics - Tetra Bio-Pharma/Panag Pharma

Latest Information Update: 15 Jun 2017

Price : $50

At a glance

  • Originator Panag Pharma
  • Developer Tetra Bio Pharma
  • Class Analgesics; Anti-inflammatories
  • Mechanism of Action Cannabinoid receptor CB2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Inflammation; Pain

Most Recent Events

  • 17 May 2017 Tetra BioPharma files for patent protection with US Patent and Trademark office for Cannabinoids and terpenoids combination
  • 14 Mar 2017 Early research in Pain (Topical) and Inflammation in USA (Ophthalmic)
  • 14 Mar 2017 Tetra Bio-Pharma enters into binding term sheet for Cannabinoid based therapeutics with Panag Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top